Nuwellis signs LOI to acquire kidney monitoring firm Rendiatech

MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE), a medical device company with a market capitalization of $3.31 million and currently trading at $6.30, announced Tuesday it has signed a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies. According to InvestingPro data, Nuwellis has seen a significant 26% return over the last week, though the stock remains highly volatile.

The proposed acquisition would expand Nuwellis’ fluid management technology platform by adding Rendiatech’s Clarity RMS, an FDA-cleared critical care monitoring system that continuously measures urine flow and sends real-time alerts to medical staff. Rendiatech is also developing a next-generation system called Clarity Prime to advance urine monitoring capabilities.

"We have embarked on a transformational growth strategy to accelerate our path to cash flow positive," said John Erb, CEO of Nuwellis. "We believe this LOI marks an important synergistic step that has the potential to be a leap forward in realizing our strategic vision." While InvestingPro analysis shows the company maintains a healthy current ratio of 2.16 and holds more cash than debt, it’s currently experiencing rapid cash burn with negative EBITDA of $9.45 million in the last twelve months. Get access to 13 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.

Avi Kleiman, CEO of Rendiatech, stated that Nuwellis’ commercial reach makes them "an ideal strategic fit as we look to scale clinical adoption."

The companies have begun a 45-day due diligence period. If both parties agree to proceed, the transaction is expected to close in the fourth quarter of 2025, pending final board approval and closing conditions.

Nuwellis currently markets the Aquadex SmartFlow system for ultrafiltration therapy, which removes excess fluid from patients suffering from hypervolemia. The company believes adding real-time monitoring technologies could strengthen its ability to deliver precise fluid management across various critical conditions.

According to the press release, acute kidney injury affects 10% to 20% of emergency hospital admissions, with an inpatient mortality over 20%. In intensive care units, the incidence rises to 20% to 50% with mortality exceeding 50%. With annual revenue of $8.32 million and a gross profit margin of 62.35%, Nuwellis is positioning itself in this critical market. For detailed healthcare sector analysis and exclusive insights on similar growth opportunities, explore the comprehensive Pro Research Reports available on InvestingPro.

In other recent news, Nuwellis Inc reported a challenging second quarter of 2025, with a significant 21% year-over-year decline in total revenue, amounting to CAD $1.7 million. The company also faced a substantial net loss during this period. Despite these operational difficulties, Nuwellis is concentrating on strategic initiatives aimed at enhancing its financial position and expanding its market presence. These developments come amid a broader effort by the company to navigate a competitive landscape and address its financial challenges. Investors are closely monitoring these efforts as Nuwellis seeks to stabilize its performance. The company’s recent financial results highlight the ongoing challenges it faces in achieving revenue growth. As Nuwellis implements its strategic plans, stakeholders remain attentive to any potential improvements in its financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.